Walmark a.s. has acquired the leading children's respiratory health brand Pneumolan from Novascon Pharmaceuticals, enhancing its market position in Poland's natural health segment.
Information on the Target
Walmark a.s. ("Walmark" or the "Company") is a leading player in the Consumer Healthcare sector in Central and Eastern Europe. The Company specializes in dietary supplements and has been jointly controlled by MidEuropa and the founding Walach family. Recently, Walmark announced a significant expansion of its product portfolio in Poland through the acquisition of the Pneumolan brand from Novascon Pharmaceuticals.
Pneumolan holds a prominent position as the leading natural respiratory health brand for children in Poland. This acquisition propels Walmark to the forefront of the natural products segment supporting respiratory health in the region, consolidating its market leadership.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Poland
The consumer healthcare industry in Poland has experienced robust growth, driven by increasing health awareness and a growing preference for natural remedies a
Similar Deals
Scanmed → Centrum Rehabilitacji Sp. z o.o.
2024
Skupina BHM → FAMED Żywiec
2023
Scanmed → Med-Lux Sp. z o.o.
2023
Labnet International, Inc. → PZ HTL S.A.
2023
THC → Centrum Medycznym Med-Gastr
Walmark a.s.
invested in
Pneumolan
in 2023
in a Buy & Build / Roll-Up deal